EE200100155A - Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni - Google Patents

Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni

Info

Publication number: EE200100155A
Authority: EE; Estonia
Prior art keywords: inhibitor; combination; treating atherosclerosis; pravastatin; employing
Prior art date: 1998-09-17

Application number

EEP200100155A

Other languages

English (en)

Estonian (et)

Inventor

A. Robl Jeffrey

A. Biller Scott

A. Parker Rex

Jamil Haris

L. Jacobson Bruce

Kodukula Krishna

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2002-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-13 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2002-08-15 Publication of EE200100155A publication Critical patent/EE200100155A/xx

Links

239000003112 inhibitor Substances 0.000 title abstract 3
201000001320 Atherosclerosis Diseases 0.000 title abstract 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
230000000879 anti-atherosclerotic effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Steroid Compounds (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Plural Heterocyclic Compounds (AREA)

EEP200100155A 1998-09-17 1999-09-13 Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni EE200100155A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10067798P	1998-09-17	1998-09-17
PCT/US1999/021069 WO2000015230A1 (en)	1998-09-17	1999-09-13	METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (1)

Publication Number	Publication Date
EE200100155A true EE200100155A (et)	2002-08-15

Family

ID=22280975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EEP200100155A EE200100155A (et)	1998-09-17	1999-09-13	Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
EEP200100154A EE04356B1 (et)	1998-09-17	1999-09-13	aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EEP200100154A EE04356B1 (et)	1998-09-17	1999-09-13	aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis

Country Status (30)

Country	Link
US (1)	US20020035064A1 (id)
EP (2)	EP1121129B1 (id)
JP (2)	JP2002524517A (id)
KR (2)	KR20010079842A (id)
CN (2)	CN1319012A (id)
AT (1)	ATE406898T1 (id)
AU (2)	AU754488B2 (id)
BG (2)	BG105432A (id)
BR (2)	BR9913831A (id)
CA (2)	CA2344300A1 (id)
CO (2)	CO5130026A1 (id)
CZ (2)	CZ2001965A3 (id)
DE (1)	DE69939481D1 (id)
EE (2)	EE200100155A (id)
ES (1)	ES2311306T3 (id)
GE (2)	GEP20033045B (id)
HU (2)	HUP0104108A2 (id)
ID (2)	ID28450A (id)
IL (2)	IL141785A0 (id)
LT (2)	LT4871B (id)
LV (2)	LV12686B (id)
NO (2)	NO20011352L (id)
NZ (2)	NZ510209A (id)
PE (2)	PE20001056A1 (id)
PL (2)	PL346660A1 (id)
SK (1)	SK3202001A3 (id)
TR (2)	TR200100774T2 (id)
UY (2)	UY25713A1 (id)
WO (2)	WO2000015230A1 (id)
ZA (2)	ZA200207433B (id)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2311125C (en) *	1997-11-19	2011-01-18	Takeda Chemical Industries, Ltd.	Apoptosis inhibitor
AU2005201289B2 (en) *	1999-02-12	2008-04-17	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
JP2002536459A (ja) *	1999-02-12	2002-10-29	プレジデントアンドフェローズオブハーヴァードカレッジ	アテローム性動脈硬化症性病変の形成の阻害
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
EP1253925A1 (en)	2000-01-28	2002-11-06	Bristol-Myers Squibb Company	Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
HUP0500543A2 (hu) *	2000-11-20	2005-09-28	Bristol-Myers Squibb Company	Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
EP1385549A2 (en) *	2001-03-12	2004-02-04	Novartis AG	Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6919323B2 (en)	2001-07-13	2005-07-19	Bristol-Myers Squibb Company	Pyridazinone inhibitors of fatty acid binding protein and method
AU2002322585A1 (en) *	2001-07-20	2003-03-03	Adipogenix, Inc.	Fat accumulation-modulating compounds
WO2003043624A1 (en)	2001-11-16	2003-05-30	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7572922B2 (en)	2003-01-27	2009-08-11	Merck & Co., Inc.	Substituted pyrazoles, compositions containing such compounds and methods of use
AU2004224825A1 (en) *	2003-03-26	2004-10-07	Crc For Asthma Limited	Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) *	2003-04-30	2004-11-11	Pfizer Products Inc.	Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
NZ549721A (en)	2004-03-05	2010-08-27	Univ Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
CN1964947A (zh)	2004-06-04	2007-05-16	默克公司	吡唑衍生物、包含其的组合物及其用法
WO2006028970A1 (en)	2004-09-02	2006-03-16	Cengent Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
SG164378A1 (en)	2005-02-17	2010-09-29	Synta Pharmaceuticals Corp	Compounds for the treatment of proliferative disorders
WO2007015999A2 (en)	2005-07-26	2007-02-08	Merck & Co., Inc.	Process for synthesizing a substituted pyrazole
JP2009511635A (ja) *	2005-10-18	2009-03-19	エージェリオンファーマシューティカルズ	哺乳動物における高脂血症に関連する障害を治療するための方法
EP2037929A4 (en) *	2006-06-02	2010-02-17	Univ San Diego State Res Found	COMPOSITIONS AND METHODS FOR REDUCING HYPERLIPIDEMIA
US20080161279A1 (en) *	2006-12-21	2008-07-03	Wisler Gerald L	Methods of Treating Obesity
US8815875B2 (en) *	2008-11-12	2014-08-26	Merck Sharp & Dohme Corp.	Inhibitors of fatty acid binding protein (FABP)
CN107141353A (zh) *	2009-03-05	2017-09-08	哈佛学院董事会	分泌的aP2及其抑制方法
JP6514282B2 (ja) *	2014-03-24	2019-05-15	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja) *	2014-03-24	2017-11-01	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
EP3288584A2 (en)	2015-04-30	2018-03-07	President and Fellows of Harvard College	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EA201990136A1 (ru) *	2016-06-27	2019-05-31	Президент Энд Феллоуз Оф Гарвард Колледж	Соединения, применимые для лечения нарушений обмена веществ
CA3066733A1 (en)	2017-06-09	2018-12-13	President And Fellows Of Harvard College	Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
EP4171736A4 (en)	2020-06-27	2024-07-03	Crescenta Biosciences	NEW CELL METABOLISM MODULATING COMPOUNDS AND THEIR USES
EP4188372A1 (en)	2020-07-29	2023-06-07	Amryt Pharmaceuticals Inc.	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2129012A1 (de)	1971-06-11	1973-01-04	Merck Patent Gmbh	Azol-derivate
FR2156486A1 (en)	1971-10-22	1973-06-01	Roussel Uclaf	Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (id)	1974-06-07	1981-03-18
GB1507032A (en)	1974-08-06	1978-04-12	Serono Lab	2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
DK277488A (da)	1987-05-22	1988-11-23	Squibb & Sons Inc	Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) *	1989-10-27	1993-06-08	American Home Products Corporation	Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) *	1989-10-27	1991-09-13	American Home Prod	Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) *	1989-12-20	1993-11-16	Bristol-Myers Squibb Company	[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr)	1990-06-14	1994-05-06	Bellon Laboratoires	Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5254576A (en) *	1992-04-03	1993-10-19	Bristol-Myers Squibb Company	Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5348969A (en) *	1992-04-03	1994-09-20	Bristol-Myers Squibb Company	Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) *	1992-04-03	1993-02-16	Bristol-Myers Squibb Company	Oxazole carboxylic acid derivatives
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5362879A (en) *	1993-04-15	1994-11-08	Bristol-Myers Squibb Company	4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de)	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JPH09506894A (ja) *	1993-12-20	1997-07-08	藤沢薬品工業株式会社	４，５−ジアリールオキサゾール誘導体
US5599770A (en)	1994-07-15	1997-02-04	Kureha Kagaku Kogyo Kabushiki Kaisha	Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt)	1994-07-29	1997-11-25	Smithkline Beecham Plc	Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk)	1995-05-08	2003-06-16	Фармація Енд Апджон Компані	<font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en)	1996-01-05	1996-03-06	Foster Wheeler Petrol Dev Ltd	Spacing bouy for flexible risers
AUPO134596A0 (en)	1996-08-01	1996-08-22	Jal Pastoral Co. Pty Ltd	Demountable article carrier for motor vehicles
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

1999
- 1999-09-13 CA CA002344300A patent/CA2344300A1/en not_active Abandoned
- 1999-09-13 BR BR9913831-0A patent/BR9913831A/pt not_active IP Right Cessation
- 1999-09-13 IL IL14178599A patent/IL141785A0/xx unknown
- 1999-09-13 KR KR1020017003408A patent/KR20010079842A/ko not_active Withdrawn
- 1999-09-13 WO PCT/US1999/021069 patent/WO2000015230A1/en not_active Ceased
- 1999-09-13 TR TR2001/00774T patent/TR200100774T2/xx unknown
- 1999-09-13 NZ NZ510209A patent/NZ510209A/en unknown
- 1999-09-13 ID IDW20010624A patent/ID28450A/id unknown
- 1999-09-13 AU AU63877/99A patent/AU754488B2/en not_active Ceased
- 1999-09-13 PL PL99346660A patent/PL346660A1/xx not_active Application Discontinuation
- 1999-09-13 JP JP2000569813A patent/JP2002524517A/ja active Pending
- 1999-09-13 EE EEP200100155A patent/EE200100155A/xx unknown
- 1999-09-13 HU HU0104108A patent/HUP0104108A2/hu unknown
- 1999-09-13 AU AU61437/99A patent/AU755563B2/en not_active Ceased
- 1999-09-13 EP EP99951438A patent/EP1121129B1/en not_active Revoked
- 1999-09-13 EE EEP200100154A patent/EE04356B1/xx not_active IP Right Cessation
- 1999-09-13 HU HU0104240A patent/HUP0104240A2/hu unknown
- 1999-09-13 CN CN99811096A patent/CN1319012A/zh active Pending
- 1999-09-13 AT AT99951438T patent/ATE406898T1/de not_active IP Right Cessation
- 1999-09-13 DE DE69939481T patent/DE69939481D1/de not_active Revoked
- 1999-09-13 TR TR2001/00773T patent/TR200100773T2/xx unknown
- 1999-09-13 GE GEAP19995860A patent/GEP20033045B/en unknown
- 1999-09-13 KR KR1020017003411A patent/KR20010075150A/ko not_active Withdrawn
- 1999-09-13 SK SK320-2001A patent/SK3202001A3/sk unknown
- 1999-09-13 CN CN99811000A patent/CN1317970A/zh active Pending
- 1999-09-13 ID IDW20010626A patent/ID27833A/id unknown
- 1999-09-13 CZ CZ2001965A patent/CZ2001965A3/cs unknown
- 1999-09-13 CA CA002344309A patent/CA2344309A1/en not_active Abandoned
- 1999-09-13 CZ CZ2001964A patent/CZ2001964A3/cs unknown
- 1999-09-13 EP EP99948210A patent/EP1113801A4/en not_active Withdrawn
- 1999-09-13 ES ES99951438T patent/ES2311306T3/es not_active Expired - Lifetime
- 1999-09-13 GE GEAP19995861A patent/GEP20033044B/en unknown
- 1999-09-13 BR BR9913833-6A patent/BR9913833A/pt not_active IP Right Cessation
- 1999-09-13 IL IL14178699A patent/IL141786A0/xx unknown
- 1999-09-13 WO PCT/US1999/020946 patent/WO2000015229A1/en not_active Ceased
- 1999-09-13 JP JP2000569814A patent/JP2002524518A/ja active Pending
- 1999-09-13 PL PL99346661A patent/PL346661A1/xx unknown
- 1999-09-13 NZ NZ510207A patent/NZ510207A/en unknown
- 1999-09-15 CO CO99058376A patent/CO5130026A1/es unknown
- 1999-09-15 CO CO99058374A patent/CO5130025A1/es unknown
- 1999-09-16 UY UY25713A patent/UY25713A1/es unknown
- 1999-09-16 UY UY25714A patent/UY25714A1/es unknown
- 1999-09-17 PE PE1999000943A patent/PE20001056A1/es not_active Application Discontinuation
- 1999-09-17 PE PE1999000944A patent/PE20001047A1/es not_active Application Discontinuation
2001
- 2001-03-16 LT LT2001022A patent/LT4871B/lt not_active IP Right Cessation
- 2001-03-16 LT LT2001023A patent/LT4870B/lt not_active IP Right Cessation
- 2001-03-16 NO NO20011352A patent/NO20011352L/no not_active Application Discontinuation
- 2001-03-16 NO NO20011351A patent/NO20011351L/no unknown
- 2001-04-10 BG BG105432A patent/BG105432A/xx unknown
- 2001-04-10 BG BG105431A patent/BG105431A/xx unknown
- 2001-04-12 LV LV010057A patent/LV12686B/xx unknown
- 2001-04-12 LV LV010058A patent/LV12687B/xx unknown
- 2001-07-13 US US09/905,235 patent/US20020035064A1/en not_active Abandoned
2002
- 2002-09-16 ZA ZA200207433A patent/ZA200207433B/en unknown
- 2002-09-16 ZA ZA200207430A patent/ZA200207430B/en unknown

Also Published As

Publication number	Publication date
HUP0104108A2 (hu)	2002-03-28
UY25714A1 (es)	2001-08-27
US20020035064A1 (en)	2002-03-21
IL141786A0 (en)	2002-03-10
NO20011352D0 (no)	2001-03-16
HUP0104240A2 (hu)	2002-03-28
AU6143799A (en)	2000-04-03
LT4871B (lt)	2001-12-27
LV12686B (lv)	2001-10-20
PE20001047A1 (es)	2000-12-24
NO20011351L (no)	2001-05-11
EE04356B1 (et)	2004-10-15
CA2344300A1 (en)	2000-03-23
ID28450A (id)	2001-05-24
EP1121129B1 (en)	2008-09-03
EP1121129A4 (en)	2002-10-16
EP1113801A4 (en)	2002-10-02
ES2311306T3 (es)	2009-02-01
EP1113801A1 (en)	2001-07-11
CN1317970A (zh)	2001-10-17
LV12687A (en)	2001-07-20
JP2002524518A (ja)	2002-08-06
KR20010079842A (ko)	2001-08-22
GEP20033044B (en)	2003-08-25
IL141785A0 (en)	2002-03-10
AU6387799A (en)	2000-04-03
SK3202001A3 (en)	2002-04-04
WO2000015230A1 (en)	2000-03-23
NZ510209A (en)	2003-07-25
BR9913831A (pt)	2001-05-29
LV12686A (en)	2001-07-20
BR9913833A (pt)	2001-05-29
BG105431A (en)	2001-12-29
CA2344309A1 (en)	2000-03-23
TR200100773T2 (tr)	2001-07-23
EP1121129A1 (en)	2001-08-08
CZ2001965A3 (cs)	2002-02-13
CZ2001964A3 (cs)	2002-01-16
LT2001023A (en)	2001-08-27
PE20001056A1 (es)	2000-12-24
NO20011351D0 (no)	2001-03-16
DE69939481D1 (de)	2008-10-16
TR200100774T2 (tr)	2001-12-21
LT2001022A (en)	2001-08-27
NZ510207A (en)	2003-08-29
UY25713A1 (es)	2001-08-27
PL346661A1 (en)	2002-02-25
WO2000015229A1 (en)	2000-03-23
LV12687B (lv)	2001-10-20
CN1319012A (zh)	2001-10-24
AU755563B2 (en)	2002-12-12
AU754488B2 (en)	2002-11-14
GEP20033045B (en)	2003-08-25
JP2002524517A (ja)	2002-08-06
EE200100154A (et)	2002-12-16
CO5130025A1 (es)	2002-02-27
PL346660A1 (en)	2002-02-25
ZA200207433B (en)	2003-10-27
ID27833A (id)	2001-04-26
KR20010075150A (ko)	2001-08-09
LT4870B (lt)	2001-12-27
NO20011352L (no)	2001-05-11
ATE406898T1 (de)	2008-09-15
CO5130026A1 (es)	2002-02-27
BG105432A (en)	2001-12-29
ZA200207430B (en)	2003-09-16

Publication	Publication Date	Title
EE200100154A (et)	2002-12-16	Suhkurtõve ravimeetod, kasutades aP2 inhibiitoritja selle kombinatsiooni
BR0317715A (pt)	2005-11-22	Composições e processos de uso de collajolie
CY2018023I1 (el)	2018-12-12	Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
DE69528528D1 (de)	2002-11-14	Thrombin-inhibitoren
ES2172657T3 (es)	2002-10-01	Inhibidores de trombina.
MX9702175A (es)	1997-06-28	Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
BR9714364A (pt)	2000-03-21	Amidas inibidoras da secreção de apo b/mtp
NO20012317L (no)	2001-07-06	Fremgangsmåte for å behandle, forhindre og redusere risikoen for at Alzheimers sykdom oppstår ved å bruke en HMG COAreduktaseinhibitor
BRPI0413468A (pt)	2006-10-17	inibidores de hmg-coa redutase baseados em pirrol
BR9901058A (pt)	2000-05-09	N-cail e n-aroil aralquil amidas.
FI944926L (fi)	1995-04-23	Entsymaattinen hydroksylaatiomenetelmä HMG-CoA-reduktaasi-inhibiittorien ja niiden välituotteiden valmistamiseksi
EA199901043A1 (ru)	2000-06-26	ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
BRPI0417138A (pt)	2007-02-21	n-alquil-pirroles como inibidores de hmg-coa-redutase
ATE429249T1 (de)	2009-05-15	Anti-fgf-8 antikörper gegen arthritis
MY140504A (en)	2009-12-31	Statin-mmp inhibitor combinations
EA200100530A1 (ru)	2001-10-22	Комбинация рилузола с альфа-токоферолом
BR0112460A (pt)	2003-07-22	Método para tratamento de sépsis
AU2002366442A1 (en)	2003-06-30	Screening method for agents useful in treating diabetes
IT1255470B (it)	1995-11-02	Composti attivi come inibitori dell'enzima hmg-coa reduttasi
ECSP992885A (es)	1999-06-11	Combinaciones de estatina-inhibidor de mmp
TH48054A (th)	2001-11-05	วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม
DE69617433D1 (de)	2002-01-10	Hemmstoff für ribonukleotid-reduktase von herpesviren